^
Association details:
| Biomarker: | PTCH1 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effects of different immune microenvironment characteristics on predictive efficacy of PTCH1 mutations in immune checkpoint inhibitor therapy of solid tumors.
Published date:
05/25/2023
Excerpt:
Patients from three independent cohorts (OAK, POPLAR and MSKCC study cohort) and were used to analyze the correlation between PTCH1 mutations and the efficacy of immune checkpoint blockade immunotherapies (ICIs)....In terms of prognostic effect with ICIs therapy, PTCH1mut were significantly associated with the overall survival (OS) of NSCLC (median, 5 months vs 11 months; HR = 1.61; 95% CI, 1.00-2.60; P = 0.049) and colorectal (median, 11 months vs 8 months; HR = 0.27; 95% CI, 0.08–0.90; P = 0.023).
DOI:
10.1200/JCO.2023.41.16_suppl.e21026
Source:
Title:
Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Published date:
05/13/2020
Excerpt:
Mutation count > 11 (tumor mutation burden (TMB)-high), age > 65, male, RNF43, CREBBP, NOTCH3, PTCH1, CIC, DNT1, and SPEN mutant (MT) were associated with longer OS, while APC-mMT and TP53-MT were significantly correlated with shorter OS….Our study is the first to elucidate comprehensive prognostic factors for the treatment of ICIs in CRC patients, from clinical characteristics such as age and sex to specific gene mutations, providing new ideas for immunotherapy in CRC.
DOI:
10.1200/JCO.2020.38.15_suppl.e16103
